Department of Anesthesia, Stanford University, Stanford, USA.
Anesth Analg. 2010 Dec;111(6):1534-42. doi: 10.1213/ANE.0b013e3181f691eb. Epub 2010 Oct 1.
BACKGROUND: In the accompanying paper, we demonstrate that genetic variation within Nalp1 could contribute to interstrain differences in wound chemokine production through altering the amount of interleukin (IL)-1 produced. We further investigate the role of IL-1 in incisional wound biology and its effect on wound chemokine production in vivo and whether this mechanism could be active in human subjects. METHODS: A well-characterized murine model of incisional wounding was used to assess the in vivo role of IL-1 in wound biology. The amount of 7 different cytokines/chemokines produced within an experimentally induced skin incision on a mouse paw and the nociceptive response was analyzed in mice treated with an IL-1 inhibitor. We also investigated whether human IL-1β or IL-1α stimulated the production of chemokines by primary human keratinocytes in vitro, and whether there was a correlation between IL-1β and chemokine levels in 2 experimental human wound paradigms. RESULTS: Administration of an IL-1 receptor antagonist to mice decreased the nociceptive response to an incisional wound, and reduced the production of multiple inflammatory mediators, including keratinocyte-derived chemokine (KC) and macrophage inhibitory protein (MIP)-1α, within the wounds. IL-1α and IL-1β stimulated IL-8 and GRO-α (human homologues of murine keratinocyte-derived chemokine) production by primary human keratinocytes in vitro. IL-1β levels were highly correlated with IL-8 in human surgical wounds, and at cutaneous sites of human ultraviolet B-induced sunburn injury. CONCLUSIONS: IL-1 plays a major role in regulating inflammatory mediator production in wounds through a novel mechanism; by stimulating the production of multiple cytokines and chemokines, it impacts clinically important aspects of wound biology. These data suggest that administration of an IL-1 receptor antagonist within the perioperative period could decrease postsurgical wound pain.
背景:在随附的论文中,我们证明 Nalp1 内的遗传变异可以通过改变白细胞介素 (IL)-1 的产生量,导致不同菌株之间在伤口趋化因子产生方面的差异。我们进一步研究了 IL-1 在切口伤口生物学中的作用及其对体内伤口趋化因子产生的影响,以及这种机制是否在人体中起作用。
方法:使用经过充分验证的小鼠切口创伤模型来评估 IL-1 在伤口生物学中的体内作用。在小鼠爪子上的实验性皮肤切口处分析了不同 7 种细胞因子/趋化因子的产生量和痛觉反应,并分析了用 IL-1 抑制剂处理的小鼠的这些情况。我们还研究了人 IL-1β 或 IL-1α 是否能刺激原代人角质形成细胞体外产生趋化因子,以及在 2 个实验性人类伤口模型中 IL-1β 与趋化因子水平之间是否存在相关性。
结果:给小鼠施用 IL-1 受体拮抗剂可降低切口伤口的痛觉反应,并减少伤口中多种炎症介质的产生,包括角质形成细胞衍生趋化因子 (KC) 和巨噬细胞抑制蛋白 (MIP)-1α。IL-1α 和 IL-1β 可刺激原代人角质形成细胞体外产生 IL-8 和 GRO-α(小鼠角质形成细胞衍生趋化因子的人同源物)。IL-1β 水平与人外科伤口中高度相关,与人类紫外线 B 诱导的晒伤损伤的皮肤部位也高度相关。
结论:IL-1 通过一种新的机制在调节伤口中炎症介质的产生方面发挥主要作用;通过刺激多种细胞因子和趋化因子的产生,它影响伤口生物学的许多临床重要方面。这些数据表明,围手术期内施用 IL-1 受体拮抗剂可能会减少术后伤口疼痛。
Anesthesiology. 2010-10
Alcohol Clin Exp Res. 2007-2
Int Wound J. 2025-5
In Vitro Model. 2025-2-21
Skin Pharmacol Physiol. 2022